Zobrazeno 1 - 10
of 81
pro vyhledávání: '"James P. Allison"'
Autor:
Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 25, iss 4
Purpose: CTLA-4 was the first inhibitory immune checkpoint to be identified. Two mAbs, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced so
Autor:
Margaret L Axelrod, Bjorn C. Knollmann, Lauren I.R. Ehrlich, Justin M. Balko, Joe-Elie Salem, James P. Allison, Javid Moslehi, Jing Wang, Padmanee Sharma, Nana Ama A.S. Anang, Jayashree Srinivasan, James J. Mancuso, Oluwatomisin T. Atolagbe, Elles M. Screever, Wouter C. Meijers, Elizabeth M. Whitley, Lorenz H. Lehmann, Lauren E. Himmel, Matthew Wleklinski, Pierre-Yves Courand, Elizabeth Wescott, Bénédicte Lebrun-Vignes, Douglas B. Johnson, Xiayu Rao, Yu Li, Spencer C. Wei, Yang Zhao
Publikováno v:
Cancer Discovery
Cancer Discovery, American Association for Cancer Research, 2020, pp.CD-20-0856. ⟨10.1158/2159-8290.CD-20-0856⟩
Cancer Discov
Cancer Discovery, American Association for Cancer Research, 2020, ⟨10.1158/2159-8290.CD-20-0856⟩
Cancer Discovery, American Association for Cancer Research, 2020, pp.CD-20-0856. ⟨10.1158/2159-8290.CD-20-0856⟩
Cancer Discov
Cancer Discovery, American Association for Cancer Research, 2020, ⟨10.1158/2159-8290.CD-20-0856⟩
Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c070a4fc8d4961377f7fa500b86553f
https://hal.sorbonne-universite.fr/hal-03099615
https://hal.sorbonne-universite.fr/hal-03099615
Autor:
Elie Tannous, Juan Qin, Wouter C. Meijers, Justin M. Balko, Yueli Zhang, Xiaopeng Sun, Margaret L Axelrod, Douglas B. Johnson, Susan R. Opalenik, Elizabeth Wescott, James P. Allison, Spencer C. Wei, Elles M. Screever, Javid Moslehi, Ayaka Sugiura
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundNearly half of all U.S. oncology patients meet FDA eligibility criteria to receive treatment with an immune checkpoint inhibitor (ICI). With increasing use of ICIs, preventing, diagnosing and treating immune-related adverse events (irAEs) a
Autor:
Rikke B. Holmgaard, Peter Palese, Dmitriy Zamarin, Padmanee Sharma, Taha Merghoub, Jacob Ricca, James P. Allison, Tamar Plitt, Jedd D. Wolchok
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Nature Communications
Nature Communications
Emerging data suggest that locoregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immunity, although the appropriate targets for intratumoral immunomodulation using this strategy are not known. Here we find
Autor:
James P. Allison, Padmanee Sharma
Publikováno v:
Nature Reviews Immunology. 20:75-76
Immune checkpoint therapy with antibodies targeting CTLA4 or PD1/PDL1 has led to durable regression of disease and cures for a subset of patients with cancer, which has led to increased efforts to develop combination immunotherapy strategies to benef
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance To overcome the challenge of nonresponsiveness or low effectiveness to current checkpoint blockade drugs, various combination therapies are under investigation for cancer treatment. In this study, we investigated a combination of Toll-li
Autor:
Christine N. Spencer, Michael A. Davies, Victor G. Prieto, Khalida Wani, Sapna Pradyuman Patel, Adi Diab, Ignacio I. Wistuba, Hong Jiang, Isabella C. Glitza, Zachary A. Cooper, Padmanee Sharma, Alexandre Reuben, Lynda Chin, Lawrence N. Kwong, Sangeetha M. Reddy, Lauren E. Haydu, Pei Ling Chen, Jorge Blando, Jacob Austin-Breneman, Qing Chang, Arlene H. Sharpe, Patrick Hwu, Michael T. Tetzlaff, Jeffrey E. Gershenwald, Vancheswaran Gopalakrishnan, Peter A. Prieto, Roland L. Bassett, Wencai Ma, Luis M Vence, Wei Shen Chen, Jianhua Hu, James P. Allison, Mariana Petaccia de Macedo, Alexander J. Lazar, Rodabe N. Amaria, R. Eric Davis, Wen-Jen Hwu, Willem W. Overwijk, Russell J. Broaddus, P. Andrew Futreal, Scott E. Woodman, Jennifer A. Wargo, John P. Miller, Whijae Roh
Publikováno v:
Cancer Discovery. 6:827-837
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and
Autor:
Padmanee Sharma, Swetha Anandhan, James P. Allison, Ana Aparicio, Hao Zhao, Liangwen Xiong, Irina Apostolou, Xuejun Zhang, Jan Zhang, Sumit K. Subudhi, Patrick Trojer, Jill Skepner, Sangeeta Goswami
Enhancer of zeste homolog 2-mediated (EZH2-mediated) epigenetic regulation of T cell differentiation and Treg function has been described previously; however, the role of EZH2 in T cell-mediated antitumor immunity, especially in the context of immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9428f6100c5935d1fc05426cf30dc557
https://europepmc.org/articles/PMC6118570/
https://europepmc.org/articles/PMC6118570/
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Publikováno v:
The Journal of Experimental Medicine
CTLA-4 blockade leads to enhanced activation of tumor-reactive T cells with concomitant up-regulation of ICOS, thus enabling their responses to be enhanced by ICOS engagement.
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal
Autor:
Jianda Yuan, James P. Allison, Yu Shen, Jingjing Sun, Padmanee Sharma, Derek Ng Tang, Sijin Wen, Jedd D. Wolchok
Publikováno v:
Cancer Immunology Research. 1:229-234
Pharmacodynamic biomarkers can play an important role in understanding whether a therapeutic agent has “hit its target” to impact biologic function. A pharmacodynamic biomarker for anti-CTLA-4 therapy remains to be elucidated. We previously repor